Immunohistochemistry evaluation of the effect in vivo of tumor necrosis factor (TNF)-α on blood vessel density in murine fibrosarcoma

Sarcoma

Volumn 7, Issue 2, 2003, Pages 57-61

  Eisenthal, Avi ^a,b   Schwartz, Ignat ^a   Issakov, Josephine ^a   Klausner, Yossef ^a   Misonzhnik, Faina ^a   Lifschitz Mercer, Beatriz ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; FEMALE; FIBROSARCOMA; GENE EXPRESSION REGULATION; GENE ISOLATION; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN VIVO STUDY; METASTASIS; METHODOLOGY; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; TISSUE SECTION; TUMOR GROWTH; VASCULARIZATION;

EID: 0042386742     PISSN: 1357714X     EISSN: None     Source Type: Journal    
DOI: 10.1080/13577140310001607275     Document Type: Article

References (21)

1. Hanahan D, Folkman J. Pattern and emerging mechanisms of angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
2. Pluda JM. Tumor-associated angiogenesis: mechanisms, clinical implications and therapeutic strategies. Semin Oncol 1997; 24: 203-18.
3. Volpert OV, Lawler J, Bouck NP. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc Natl Acad Sci USA 1998; 95: 6343-8.
4. Torishu H, Ono M, Kiryu H, Furue M, Ohmoto Y, Nakayama J, Nishioka Y, Sone S, Kuwano M. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNF alpha and IL-1 alpha. Int J Cancer 2000; 85: 182-8.
5. Carswell EA, Old LJ, Kassel RC, Green S, Fiore N, Wiliamson BD. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72: 3666-70.
6. Soengas MS, Alarcon RM, Yoshida H, Giaccia AJ, Hakem R, Mak TW, Lowe SW. Apaf-1 and caspase-9 in p53 dependent apoptosis and tumor inhibition. Science 1999; 284: 156-9.
7. Yoshimura H, Chikamoto A, Honda T, Tashiro K, Nakamoto T, Takano M, Takagi K, Nagasue N, Soma G. Relation between microvessel quantification and inducibility of endogenous tumor necrosis factor in colorectal adenocarcinoma. Anticancer Res 2000; 20: 629-33.
8. Joseph IB, Isaacs JT. Macrophages role in antiprostate cancer response to one class of antiangiogenic agents. J Natl Cancer Inst 1998; 90: 1648-53.
9. Feleszko W, Balkowiec EZ, Sieberth E, Marczak M, Dabrowska A, Giermasz A, Czajka A, Jakobisiak M. Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis. Int J Cancer 1999; 81: 560-7.
10. Brem H, Folkman J. Analysis of experimental antiangiogenic therapy. J Pediatr Surg 1993; 28: 445-50.
11. McIntosh JK, Mule JJ, Merino MJ, Rosenberg SA. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-α. Cancer Res 1988; 48: 4011-17.
12. Eisenthal A, Polyvkin N, Bramante-Schreiber L, Misonznik F, Hasner A, Lifschitz-Mercer B. Expression of dendritic cells (DC) in ovarian tumors correlates with the clinical outcome in ovarian cancer patients. Hum Pathol 2001; 32: 803-7.
13. Gutman M, Sofer D, Lev-Chelouche D, Merimsky O, Klausner JM. Synergism of tumor necrosis factor-α and melphalan in systemic and regional administration: animal study. Invasion Metastasis 1997; 17: 169-75.
14. Asher AL, Mule JJ, Reichert CM, Shiloni E, Rosenberg SA. Studies of the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 1987; 138: 963-74.
15. Palladino MA, Shalby MR, Krammer SM, Ferraiolo BL, Baughman RA, Deleo AB, Crase D, Marafino B, Aggarwal BB, Figari IS, Liggitt D, Patton JS. Characterization of the antitumor activities of human tumor necrosis factor-α and the comparison with other cytokines: induction of tumor-specific immunity. J Immunol 1987; 138: 4023-32.
16. Okuyama M, Yamaguchi S, Yamaoka M, Nitobe J, Fujii S, Yoshimura T, Tomoike H. Nitric oxide enhances expression and shedding of tumor necrosis factor receptor I (p55) in endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20: 1506-11.
17. Leek RD, Hunt NC, Landers RJ, Lewis CE, Royds JA, Harris AL. Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol 2000; 190: 430-6.
18. De-Assis MC, Da-Costa AO, Barja-Fidalgo TC, Plotkowski MC. Human endothelial cells are activated by interferon-gamma plus tumour necrosis factor-alpha to kill intracellular Pseudomonas aeruginosa. Immunology 2000; 101: 271-8.
19. Nathan I, Dizdaroglu M, Bernstein L, Junker U, Lee C, Muegge K, Durum SK. Induction of oxidative DNA damage in u937 cells by TNF or anti-Fas stimulation. Cytokine 2000; 12: 881-7.
20. Ogata N, Yamamoto H, Kugiyama K, Yasue H, Miyamoto E. Involvement of protein kinase C in superoxide anion-induced activation of nuclear factor-kappa B in human endothelial cells. Cardiovasc Res 2000; 45: 513-21.
21. Mazanet R, Antman KH. Sarcomas of soft tissue and bone. Cancer 1991; 68: 463-73.